Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29042417.
- Also identified by DOI 10.1158/0008-5472.CAN-17-1032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint therapies target tumor antigen-specific T cells, but less is known about their effects on natural killer (NK) cells, which help control metastasis. In studying the development of lung metastases, we found that NK cells lose their cytotoxic capacity and acquire a molecular signature defined by the expression of coinhibitory receptors. In an effort to overcome this suppressive mechanism, we evaluated NK cell responses to the immunostimulatory cytokine IL12. Exposure to IL12 rescued the cytotoxicity of NK cells but also led to the emergence of an immature NK cell population that expressed high levels of the coinhibitory molecules PD-1, Lag-3, and TIGIT, thereby limiting NK cell-mediated control of pulmonary metastases. Notably, checkpoint blockade therapy synergized with IL12 to fully enable tumor control by NK cells, demonstrating that checkpoint blockers are not only applicable to enhance T cell-mediated immunotherapy, but also to restore the tumor-suppressive capacity of NK cells. <i>Cancer Res; 77(24); 7059-71. ©2017 AACR</i>.
Medical subject headings
- Cell Cycle Checkpoints
- Cytotoxicity, Immunologic
- Interleukin-12
- Killer Cells, Natural
- Mammary Neoplasms, Experimental
- Molecular Targeted Therapy
- Neoplasm Metastasis